S100A16 up‑regulates Oct4 and Nanog expression in cancer stem‑like cells of Yumoto human cervical carcinoma cells

Tomiyama,Nariaki; Ikeda,Ryuji; Nishizawa,Yukihiko; Masuda,Shogo; Tajitsu,Yusuke; Takeda,Yasuo

doi:10.3892/ol.2018.8568

S100A16 up‑regulates Oct4 and Nanog expression in cancer stem‑like cells of Yumoto human cervical carcinoma cells

Authors:
- Nariaki Tomiyama
- Ryuji Ikeda
- Yukihiko Nishizawa
- Shogo Masuda
- Yusuke Tajitsu
- Yasuo Takeda
View Affiliations

Affiliations: Department of Clinical Pharmacy and Pharmacology, Graduate School of Medical and Dental Sciences, Kagoshima University, Kagoshima 890‑8520, Japan, Department of Pharmacy, Izumi General Medical Center, Izumi‑shi, Kagoshima 899‑0131, Japan
Published online on: April 25, 2018 https://doi.org/10.3892/ol.2018.8568
Pages: 9929-9933

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Cancer stem‑like cells (CSCs), which possess the ability to self‑renewal and are multipotent, are regarded as the cause of tumor formation, recurrence, metastasis and drug resistance. It is necessary to understand the properties of CSCs in order to treat them effectively. It has been previously reported that S100 family proteins, which carry calcium‑binding EF‑hand motifs and are associated with tumorigenic processes, serve crucial roles in maintaining cancer stem‑like properties. S100A16 is upregulated in various types of cancer, including bladder, lung and pancreatic. However, the roles of S100A16 in cancer cells, particularly CSCs, are not clear. The present study investigated the roles of S100A16 in CSCs using the sphere formation assay of Yumoto cells, which are a human cervical carcinoma cell line. The mRNA expression levels were evaluated by reverse transcription‑polymerase chain reaction and the protein expression levels were detected by western blot analysis. Following the sphere formation of Yumoto cells, the mRNA and protein expression level of Oct4, Nanog and S100A16 were increased compared with the control cells. Following transfection with S100A16 small interfering RNA (siRNA), the mRNA and protein expression of Oct4 and Nanog were decreased and the spheroid size was significantly decreased in the sphere formation of Yumoto cells compared with control siRNA treated cells. There was no change in the p53 mRNA expression level, whereas the p53 protein expression level, which was decreased by the sphere formation, was recovered by S100A16 knockdown. In addition, the protein expression levels of Oct4 and Nanog, which were increased in the sphere formation, were decreased by the proteasome inhibitor lactacystin. No differences were observed in the S100A16 protein expression between the presence or absence of lactacystin. These results suggest that S100A16 serves an important role in the CSCs of human cervical carcinoma and is a positive regulator of Oct4 and Nanog.

View Figures

View References

1	Jordan CT, Guzman ML and Noble M: Cancer stem cells. N Engl J Med. 355:1253–1261. 2006. View Article : Google Scholar : PubMed/NCBI
2	Rosner MH, Vigano MA, Ozato K, Timmons PM, Poirier F, Rigby PW and Staudt LM: A POU-domain transcription factor in early stem cells and germ cells of the mammalian embryo. Nature. 345:686–692. 1990. View Article : Google Scholar : PubMed/NCBI
3	Kumar SM, Liu S, Lu H, Zhang H, Zhang PJ, Gimotty PA, Guerra M, Guo W and Xu X: Acquired cancer stem cell phenotypes through Oct4-mediated dedifferentiation. Oncogene. 31:4898–4911. 2012. View Article : Google Scholar : PubMed/NCBI
4	Jeter CR, Yang T, Wang J, Chao HP and Tang DG: Concise review: NANOG in cancer stem cells and tumor development: An update and outstanding questions. Stem Cells. 33:2381–2390. 2015. View Article : Google Scholar : PubMed/NCBI
5	Chambers I, Colby D, Robertson M, Nichols J, Lee S, Tweedie S and Smith A: Functional expression cloning of Nanog, a pluripotency sustaining factor in embryonic stem cells. Cell. 113:643–655. 2003. View Article : Google Scholar : PubMed/NCBI
6	Savage P: Chemotherapy curable malignancies and cancer stem cells: A biological review and hypothesis. BMC Cancer. 16:9062016. View Article : Google Scholar : PubMed/NCBI
7	Chen H, Xu C, Jin Q and Liu Z: S100 protein family in human cancer. Am J Cancer Res. 4:89–115. 2014.PubMed/NCBI
8	Bresnick AR, Weber DJ and Zimmer DB: S100 proteins in cancer. Nat Rev Cancer. 15:96–109. 2015. View Article : Google Scholar : PubMed/NCBI
9	Marenholz I and Heizmann CW: S100A16, a ubiquitously expressed EF-hand protein which is up-regulated in tumors. Biochem Biophys Res Commun. 313:237–244. 2004. View Article : Google Scholar : PubMed/NCBI
10	Zhou W, Pan H, Xia T, Xue J, Cheng L, Fan P, Zhang Y, Zhu W, Xue Y, Liu X, et al: Up-regulation of S100A16 expression promotes epithelial-mesenchymal transition via Notch1 pathway in breast cancer. J Biomed Sci. 21:972014. View Article : Google Scholar : PubMed/NCBI
11	Liu Y, Zhang R, Xin J, Sun Y, Li J, Wei D and Zhao AZ: Identification of S100A16 as a novel adipogenesis promoting factor in 3T3-L1 cells. Endocrinology. 152:903–911. 2011. View Article : Google Scholar : PubMed/NCBI
12	Chiou SH, Wang ML, Chou YT, Chen CJ, Hong CF, Hsieh WJ, Chang HT, Chen YS, Lin TW, Hsu HS and Wu CW: Coexpression of Oct4 and Nanog enhances malignancy in lung adenocarcinoma by inducing cancer stem cell-like properties and epithelial-mesenchymal transdifferentiation. Cancer Res. 70:10433–10444. 2010. View Article : Google Scholar : PubMed/NCBI
13	Thiery JP, Acloque H, Huang RY and Nieto MA: Epithelial-mesenchymal transitions in development and disease. Cell. 139:871–890. 2009. View Article : Google Scholar : PubMed/NCBI
14	Abdelalim EM and Tooyama I: Knockdown of p53 suppresses Nanog expression in embryonic stem cells. Biochem Biophys Res Commun. 443:652–657. 2014. View Article : Google Scholar : PubMed/NCBI
15	Lin J, Yang Q, Wilder PT, Carrier F and Weber DJ: The calcium-binding protein S100B down-regulates p53 and apoptosis in malignant melanoma. J Biol Chem. 285:27487–27498. 2010. View Article : Google Scholar : PubMed/NCBI
16	Orre LM, Panizza E, Kaminskyy VO, Vernet E, Gräslund T, Zhivotovsky B and Lehtiö J: S100A4 interacts with p53 in the nucleus and promotes p53 degradation. Oncogene. 32:5531–5540. 2013. View Article : Google Scholar : PubMed/NCBI
17	Pastrana E, Silva-Vargas V and Doetsch F: Eyes wide open: A critical review of sphere-formation as an assay for stem cells. Cell Stem Cell. 8:486–498. 2011. View Article : Google Scholar : PubMed/NCBI
18	Wei B, Han XY, Qi CL, Zhang S, Zheng ZH, Huang Y, Chen TF and Wei HB: Coaction of spheroid-derived stem-like cells and endothelial progenitor cells promotes development of colon cancer. PLoS One. 7:e390692012. View Article : Google Scholar : PubMed/NCBI
19	Fujii H, Honoki K, Tsujiuchi T, Kido A, Yoshitani K and Takakura Y: Sphere-forming stem-like cell populations with drug resistance in human sarcoma cell lines. Int J Oncol. 34:1381–1386. 2009.PubMed/NCBI
20	Chen YC, Hsu HS, Chen YW, Tsai TH, How CK, Wang CY, Hung SC, Chang YL, Tsai ML, Lee YY, et al: Oct-4 expression maintained cancer stem-like properties in lung cancer-derived CD133-positive cells. PLoS One. 3:e26372008. View Article : Google Scholar : PubMed/NCBI
21	Hollstein M, Sidransky D, Vogelstein B and Harris CC: p53 mutations in human cancers. Science. 253:49–53. 1991. View Article : Google Scholar : PubMed/NCBI
22	Levine AJ, Momand J and Finlay CA: The p53 tumour suppressor gene. Nature. 351:453–456. 1991. View Article : Google Scholar : PubMed/NCBI
23	Naniwa J, Kigawa J, Akeshima R, Kanamori Y, Itamochi H, Oishi T, Iba T and Terakawa N: Leptomycin B enhances CDDP-sensitivity via nuclear accumulation of p53 protein in HPV-positive cells. Cancer Sci. 94:1099–1103. 2003. View Article : Google Scholar : PubMed/NCBI
24	Xu HM, Liao B, Zhang QJ, Wang BB, Li H, Zhong XM, Sheng HZ, Zhao YX, Zhao YM and Jin Y: Wwp2, an E3 ubiquitin ligase that targets transcription factor Oct-4 for ubiquitination. J Biol Chem. 279:23495–23503. 2004. View Article : Google Scholar : PubMed/NCBI
25	Floyd ZE, Staszkiewicz J, Power RA, Kilroy G, Kirk-Ballard H, Barnes CW, Strickler KL, Rim JS, Harkins LL, Gao R, et al: Prolonged proteasome inhibition cyclically upregulates Oct3/4 and Nanog gene expression, but reduces induced pluripotent stem cell colony formation. Cell Reprogram. 17:95–105. 2015. View Article : Google Scholar : PubMed/NCBI
26	Vlashi E, Kim K, Lagadec C, Donna LD, McDonald JT, Eghbali M, Sayre JW, Stefani E, McBride W and Pajonk F: In vivo imaging, tracking, and targeting of cancer stem cells. J Natl Cancer Inst. 101:350–359. 2009. View Article : Google Scholar : PubMed/NCBI
27	Tanaka M, Ichikawa-Tomikaw N, Shishito N, Nishiura K, Miura T, Hozumi A, Chiba H, Yoshida S, Ohtake T and Sugino T: Co-expression of S100A14 and S100A16 correlates with a poor prognosis in human breast cancer and promotes cancer cell invasion. BMC Cancer. 13:532015. View Article : Google Scholar
28	Saito K, Kobayashi M, Nagashio R, Ryuge S, Katono K, Nakashima H, Tsuchiya B, Jiang SX, Saegusa M, Satoh Y, et al: S100A16 is a prognostic marker for lung adenocarcinomas. Asian Pac J Cancer Prev. 16:7039–7044. 2015. View Article : Google Scholar : PubMed/NCBI
29	Sapkota D, Bruland O, Parajuli H, Osman TA, Teh MT, Johannessen AC and Costea DE: S100A16 promotes differentiation and contributes to a less aggressive tumor phenotype in oral squamous cell carcinoma. BMC Cancer. 15:6312015. View Article : Google Scholar : PubMed/NCBI